Glucophage Sr

Glucophage Sr is an oral prescription tablet whose active ingredient is metformin hydrochloride, a biguanide indicated for type 2 diabetes mellitus in patients with inadequate glycemic control. Available in the European Union, the product is supplied in varying tablet strengths and works by reducing hepatic glucose production and enhancing peripheral insulin sensitivity. It is classified under ATC code A10BA02 and is used as part of a broader diabetes management strategy.

Glucophage Sr is prescribed primarily for the management of type 2 diabetes mellitus.

- As initial monotherapy for adults whose diet and exercise alone do not achieve target glycemic levels. - In combination with other oral antidiabetic agents when additional glucose lowering is needed. - As adjunct therapy with insulin to improve overall glycemic control. - To help reduce the risk of diabetes‑related complications when used as part of a comprehensive treatment plan. - Occasionally used off‑label for conditions such as polycystic ovary syndrome under specialist supervision.

Side effects of Glucophage Sr vary in frequency and severity.

Common: - Gastrointestinal upset, including nausea, vomiting, or abdominal discomfort. - Diarrhea or loose stools. - Metallic taste in the mouth. - Decreased appetite. - Mild skin rash or itching.

Serious: - Lactic acidosis, a rare but potentially life‑threatening metabolic condition. - Severe hypoglycemia when combined with other glucose‑lowering drugs. - Hepatotoxicity manifested by elevated liver enzymes. - Persistent or worsening gastrointestinal symptoms that may indicate intolerance. - Allergic reactions such as angioedema or severe skin eruptions.

Before starting Glucophage Sr, certain precautions should be considered.

- Assess renal function; avoid use in patients with severe renal impairment. - Monitor liver enzymes periodically, especially in patients with existing hepatic disease. - Use cautiously in the elderly, who may have reduced renal clearance. - Discontinue before any radiographic studies that use iodinated contrast agents. - Educate patients about signs of lactic acidosis and advise immediate medical attention if they occur. - Review pregnancy and breastfeeding status; the safety profile is not fully established.

Glucophage Sr can interact with several medications, requiring attention to avoid adverse outcomes.

Avoid: - Iodinated contrast media used in imaging studies, due to risk of acute renal failure. - Cimetidine, which may increase metformin plasma concentrations. - Certain diuretics that can impair renal function and elevate metformin levels.

Use with caution: - Alcohol, which may increase the risk of lactic acidosis. - Beta‑blockers, as they can mask hypoglycemia symptoms. - Other antidiabetic agents, to prevent excessive lowering of blood glucose. - Corticosteroids, which may raise blood glucose and affect metformin efficacy.